Oncologia Medica, Istituto Oncologico Veneto - IRCCS, Padova, Italy.
Anticancer Drugs. 2010 Feb;21(2):210-3. doi: 10.1097/CAD.0b013e3283340d1f.
In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-alpha in a patient who failed classical sunitinib treatment.
近年来，随着贝伐珠单抗、舒尼替尼、索拉非尼、替西罗莫司和依维莫司等靶向药物的发展，转移性肾细胞癌的治疗发生了巨大变化。在临床实践中，舒尼替尼和贝伐珠单抗被保留用于一线治疗，但尽管有各种指南，最佳治疗方案仍不确定。我们首次报道了一例经典舒尼替尼治疗失败的患者二线使用贝伐珠单抗和干扰素-α治疗后获得良好反应的病例。
